Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

: ComparativeParticipantFlowEvidence: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial - JSON Representation

Raw json | Download

{
  "resourceType" : "Evidence",
  "id" : "179635",
  "meta" : {
    "versionId" : "6",
    "lastUpdated" : "2024-05-16T17:39:42.860Z",
    "profile" : [
      🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-participant-flow-evidence"
    ]
  },
  "text" : {
    "status" : "generated",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: Evidence 179635</b></p><a name=\"179635\"> </a><a name=\"hc179635\"> </a><a name=\"179635-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">version: 6; Last updated: 2024-05-16 17:39:42+0000</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-comparative-participant-flow-evidence.html\">ComparativeParticipantFlowEvidence</a></p></div><p><b>url</b>: <a href=\"https://fevir.net/resources/Evidence/179635\">https://fevir.net/resources/Evidence/179635</a></p><p><b>identifier</b>: FEvIR Object Identifier/179635</p><p><b>name</b>: ComparativeParticipantFlowEvidence_Dropout_due_to_stopping_intervention_Lofexidine_vs_Placebo_in_opioid_detoxification_trial</p><p><b>title</b>: ComparativeParticipantFlowEvidence: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial</p><p><b>status</b>: Active</p><p><b>publisher</b>: Computable Publishing LLC</p><p><b>contact</b>: <a href=\"mailto:support@computablepublishing.com\">support@computablepublishing.com</a></p><p><b>author</b>: Brian S. Alper: </p><h3>UseContexts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"CodeSystem-179423.html#179423-evidence-communication\">Evidence Based Medicine on FHIR Implementation Guide Code System evidence-communication</a>: Evidence Communication</td><td><span title=\"Codes:{https://fevir.net/resources/CodeSystem/179423 ComparativeParticipantFlowEvidence}\">ComparativeParticipantFlowEvidence</span></td></tr></table><p><b>copyright</b>: </p><div><p>https://creativecommons.org/licenses/by-nc-sa/4.0/</p>\n</div><h3>RelatedArtifacts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Citation</b></td><td><b>ResourceReference</b></td></tr><tr><td style=\"display: none\">*</td><td>Cite As</td><td><div><p>ComparativeParticipantFlowEvidence: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial [Database Entry: FHIR Evidence Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179635. Revised 2024-05-16. Available at: https://fevir.net/resources/Evidence/179635. Computable resource at: https://fevir.net/resources/Evidence/179635.</p>\n</div></td><td> </td></tr><tr><td style=\"display: none\">*</td><td>Derived From</td><td> </td><td><a href=\"Citation-179637.html\">18508207 A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal</a></td></tr></table><p><b>description</b>: </p><div><p>Dropout due to stopping intervention 18/33 with Lofexidine vs. 12/35 with Placebo in opioid detoxification trial</p>\n</div><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Participants in the opioid detoxification trial</p>\n</div><p><b>variableRole</b>: Population</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>GroupAssignment: Lofexidine vs. Placebo</p>\n</div><p><b>variableRole</b>: Exposure</p><p><b>comparatorCategory</b>: false</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Dropout due to stopping intervention</p>\n</div><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"EvidenceVariable-179636.html\">PartiicipantFlowMeasure: Dropout due to stopping intervention</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>description</b>: </p><div><p>18/33 (54.5%) with Lofexidine vs. 12/35 (34.3%) with Placebo (relative risk 1.59, p &lt; 0.01)</p>\n</div><p><b>statisticType</b>: <span title=\"Codes:{https://fevir.net/resources/CodeSystem/181513 STATO:0000245}\">Risk Ratio</span></p><p><b>quantity</b>: 1.59</p><p><b>numberAffected</b>: 30</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>NumberOfParticipants</b></td></tr><tr><td style=\"display: none\">*</td><td>68</td></tr></table><h3>AttributeEstimates</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Description</b></td><td><b>Type</b></td><td><b>Quantity</b></td></tr><tr><td style=\"display: none\">*</td><td><div><p>p &lt; 0.01</p>\n</div></td><td><span title=\"Codes:{https://fevir.net/resources/CodeSystem/181513 TBD:0000076}\">P-value</span></td><td>&lt;0.01</td></tr></table></blockquote></div>"
  },
  "url" : "https://fevir.net/resources/Evidence/179635",
  "identifier" : [
    {
      "type" : {
        "coding" : [
          {
            "system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
            "code" : "ACSN",
            "display" : "Accession ID"
          }
        ],
        "text" : "FEvIR Object Identifier"
      },
      "system" : "https://fevir.net",
      "value" : "179635",
      "assigner" : {
        "display" : "Computable Publishing LLC"
      }
    }
  ],
  "name" : "ComparativeParticipantFlowEvidence_Dropout_due_to_stopping_intervention_Lofexidine_vs_Placebo_in_opioid_detoxification_trial",
  "title" : "ComparativeParticipantFlowEvidence: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial",
  "status" : "active",
  "publisher" : "Computable Publishing LLC",
  "contact" : [
    {
      "telecom" : [
        {
          "system" : "email",
          "value" : "support@computablepublishing.com"
        }
      ]
    }
  ],
  "author" : [
    {
      "name" : "Brian S. Alper"
    }
  ],
  "useContext" : [
    {
      "code" : {
        "system" : "https://fevir.net/resources/CodeSystem/179423",
        "code" : "evidence-communication",
        "display" : "Evidence Communication"
      },
      "valueCodeableConcept" : {
        "coding" : [
          {
            "system" : "https://fevir.net/resources/CodeSystem/179423",
            "code" : "ComparativeParticipantFlowEvidence",
            "display" : "ComparativeParticipantFlowEvidence"
          }
        ]
      }
    }
  ],
  "copyright" : "https://creativecommons.org/licenses/by-nc-sa/4.0/",
  "relatedArtifact" : [
    {
      "type" : "cite-as",
      "citation" : "ComparativeParticipantFlowEvidence: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial [Database Entry: FHIR Evidence Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179635. Revised 2024-05-16. Available at: https://fevir.net/resources/Evidence/179635. Computable resource at: https://fevir.net/resources/Evidence/179635."
    },
    {
      "type" : "derived-from",
      "resourceReference" : {
        🔗 "reference" : "Citation/179637",
        "type" : "Citation",
        "display" : "18508207 A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal"
      }
    }
  ],
  "description" : "Dropout due to stopping intervention 18/33 with Lofexidine vs. 12/35 with Placebo in opioid detoxification trial",
  "variableDefinition" : [
    {
      "description" : "Participants in the opioid detoxification trial",
      "variableRole" : "population"
    },
    {
      "description" : "GroupAssignment: Lofexidine vs. Placebo",
      "variableRole" : "exposure",
      "comparatorCategory" : "false"
    },
    {
      "description" : "Dropout due to stopping intervention",
      "variableRole" : "outcome",
      "observed" : {
        🔗 "reference" : "EvidenceVariable/179636",
        "type" : "EvidenceVariable",
        "display" : "PartiicipantFlowMeasure: Dropout due to stopping intervention"
      }
    }
  ],
  "statistic" : [
    {
      "description" : "18/33 (54.5%) with Lofexidine vs. 12/35 (34.3%) with Placebo (relative risk 1.59, p < 0.01)",
      "statisticType" : {
        "coding" : [
          {
            "system" : "https://fevir.net/resources/CodeSystem/181513",
            "code" : "STATO:0000245",
            "display" : "Risk Ratio"
          }
        ]
      },
      "quantity" : {
        "value" : 1.59
      },
      "numberAffected" : 30,
      "sampleSize" : {
        "numberOfParticipants" : 68
      },
      "attributeEstimate" : [
        {
          "description" : "p < 0.01",
          "type" : {
            "coding" : [
              {
                "system" : "https://fevir.net/resources/CodeSystem/181513",
                "code" : "TBD:0000076",
                "display" : "P-value"
              }
            ]
          },
          "quantity" : {
            "value" : 0.01,
            "comparator" : "<"
          }
        }
      ]
    }
  ]
}